NCT05290090View on ClinicalTrials.gov

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

June 1, 2024

Study Completion Date

December 1, 2025

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Rituximab, Lenalidomide, Zanubrutinib and RCHOP

"chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER